Halozyme confirms ‘positive’ results from Bristol Myers’ Phase 3 CheckMate-67T

Halozyme Therapeutics (HALO) announced that Bristol Myers Squibb (BMY) reported positive topline results from the Phase 3 CheckMate-67T trial evaluating a subcutaneous formulation of Opdivo with ENHANZE in patients with advanced or metastatic clear cell renal cell carcinoma who have received prior systemic therapy. The study met its co-primary pharmacokinetics endpoints and key secondary endpoint.